secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001104659-25-045067
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q1 net income $11.4M vs loss; revenue $53.3M (+68% YoY); 2025 outlook reaffirmed
--------------------------------------------------------------------------------

- Net product sales $43.6M up 68% YoY: TAVALISSE $28.5M (+35%), GAVRETO $9.0M, REZLIDHIA $6.1M (+25%).
- R289 granted FDA Orphan Drug (MDS) and Fast Track (lower-risk MDS); Phase 1b enrolling sixth dose level.
- Patent settlement with Annora allows generic TAVALISSE license in Q2 2032 or earlier; litigation terminated.
- Will not opt-in for ocadusertib; expects $40M non-cash revenue in Q2 from release of cost-share liability.
- 2025 outlook: total revenue $200-210M (excl. $40M one-time); positive net income expected for full year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465925045067/0001104659-25-045067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465925045067/tm2514128d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-045067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer